How much funding has Code Biotherapeutics raised?

Code Biotherapeutics has raised $85.0M in total funding, most recently a Series A round.

Who are Code Biotherapeutics's investors?

Code Biotherapeutics's investors include 4BIO Capital, Northpond Ventures, Amgen, Hatteras Venture Partners, UCB, UPMC Enterprises.

When was Code Biotherapeutics founded?

Code Biotherapeutics was founded in 2021.

Where is Code Biotherapeutics headquartered?

Code Biotherapeutics is headquartered in Hatfield, Pennsylvania, United States.

What industry is Code Biotherapeutics in?

Code Biotherapeutics operates in Biotech, Therapeutics.

How many employees does Code Biotherapeutics have?

Code Biotherapeutics has 11-50 employees.

Code Biotherapeutics

Pioneering Targeted Delivery of Genetic Medicines

Hatfield, United States · Founded 2021 · $85.0M raised

Biotech

Therapeutics

Headquarters: Hatfield, Pennsylvania
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: codebiotx.com
Total Funding: $85.0M
Last Round: $75.0M Series AJun 2022
Rounds: 2

About

Code Biotherapeutics is a preclinical-stage genetic medicine company developing transformational non-viral delivery of genetic medicines using its proprietary 3DNA® platform. The 3DNA platform is a multivalent synthetic DNA scaffold engineered to overcome key challenges in genetic medicine delivery including dose-related toxicity and immunogenicity. Code Bio's most advanced program targets Duchenne Muscular Dystrophy.

Summary

Code Biotherapeutics is a Biotech company based in Hatfield, United States, founded in 2021. It has raised $85.0M in total across 2 rounds, most recently a $75.0M Series A round in Jun 2022. Investors include 4BIO Capital, Northpond Ventures and Amgen.

LinkedIn X (Twitter)